Carfilzomib through a liver pump for people with liver cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new drug called carfilzomib given directly into the liver through an HAI pump. It is for people whose cancer has spread mainly to the liver and who have already tried floxuridine therapy through the pump. The goal is to see if this drug can help control the cancer in the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancer types: colorectal cancer, intrahepatic cholangiocarcinoma, or adrenocortical carcinoma.
- Most of your cancer (at least 75%) must be in the liver.
- You must already have an HAI pump (a small device that delivers chemotherapy directly to the liver) and it must be working.
- You must have received floxuridine through the pump before and either it stopped working, you couldn't tolerate it, or you still have cancer after treatment.
- You must be 18 years or older and in generally good health (able to care for yourself; some exceptions allowed).
- Your liver, kidney, and blood cell counts must be within certain acceptable ranges, and you must not have had radiation therapy to the liver before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
This Phase 2 study tests gemcitabine plus oxaliplatin chemotherapy, and whether adding a chemotherapy pump (with floxuridine and dexamethasone) delivered to the liver improves outcomes. It is for people whose intrahepatic cholangiocarcinoma cannot be removed with surgery.
This trial tests a treatment approach where you receive chemotherapy directly into your liver through a surgically placed pump, combined with standard systemic chemotherapy (given through a vein). The goal is to shrink liver tumors enough so they can be removed later with surgery. It is for people whose colorectal cancer has spread only to the liver and has not been treated before.
This trial tests whether giving extra chemotherapy directly to the liver through a small pump (called HAIP) before or after surgery can improve outcomes for patients with bile duct cancer inside the liver. It is for patients whose cancer is considered removable by surgery.
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.